Shots:

• Alopexx and Bharat Biotech have partnered to co-develop & commercialize the former’s AV0328, a broad-spectrum anti-microbial vaccine, across India as well as other low income & lower middle-income countries
• Bharat Biotech will pay one-time upfront, milestones as well as sales-based royalties linked to AV0328 in the licensed territories
• AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), was effective against 15 distinct pathogens in preclinical study and well-tolerated in P-I study without any SAEs. It produced antibodies that effectively killed a variety of PNAG-expressing pathogens, showing promise as a broad-spectrum antimicrobial solution

Ref: Globenewswire | Image: Alopexx & Bharat Biotech

Related News: Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com